What is NASH (Non-Alcoholic Steatohepatitis)?
NASH is a severe inflammatory form of fatty liver disease characterized by the presence of ≥5% hepatic steatosis (fat accumulation) combined with hepatocyte injury (specifically ballooning degeneration) and inflammation, with or without fibrosis, occurring in the absence of significant alcohol consumption. 1
Key Defining Features
NASH represents the more aggressive subtype within the spectrum of non-alcoholic fatty liver disease (NAFLD) and is distinguished from simple fatty liver (NAFL) by three critical histologic components:
- Steatosis: ≥5% fat accumulation in hepatocytes
- Inflammation: Lobular inflammation with immune cell infiltration
- Hepatocyte injury: Ballooning degeneration of liver cells (the hallmark feature that separates NASH from simple steatosis)
- Fibrosis: May or may not be present, but when present indicates more advanced disease 1
Clinical Significance and Natural History
NASH can progress to cirrhosis, liver failure, and hepatocellular carcinoma, making it fundamentally different from simple fatty liver which carries minimal risk of progression. 1 Approximately 20% of patients with NASH will develop cirrhosis 2, and NASH is predicted to become the leading indication for liver transplantation in the United States 2.
The mortality implications are substantial:
- Annual all-cause mortality rate: 25.56 per 1,000 person-years
- Liver-specific mortality rate: 11.77 per 1,000 person-years 2
Epidemiology and Risk Factors
NASH affects an estimated 3-6% of the US population 2, though this represents only a subset of the approximately 25% of the general population with NAFLD 3, 1. The disease is strongly associated with metabolic dysfunction:
- Obesity (most common association)
- Type 2 diabetes mellitus
- Dyslipidemia
- Metabolic syndrome
- Insulin resistance 1, 2
Pathophysiology
NASH develops when hepatocytes are injured by lipids (lipotoxicity) 4. The condition represents a necro-inflammatory wound-healing response to lipotoxic injury. Lipid peroxidation and oxidative stress are the primary mechanisms driving hepatocyte damage 5. The liver becomes programmed toward lipogenesis rather than glycogenesis, with insulin resistance playing a central role 6.
Diagnostic Approach
Liver biopsy remains the only accepted method for definitive diagnosis of NASH 2, as it is the only way to distinguish NASH from simple steatosis and to assess the degree of inflammation, ballooning, and fibrosis. While noninvasive tests and scoring systems exist to characterize NAFLD, they cannot definitively diagnose NASH 2.
Clinical Presentation
Most patients with NASH are asymptomatic 5. When present, the most common clinical findings include:
- Hepatomegaly (most common physical sign)
- Elevated serum aminotransferases (typically 2-4 fold elevation)
- Other liver function tests usually remain normal
- Stigmata of chronic liver disease are rare until cirrhosis develops 5
Important Clinical Caveat
NASH is severely underrecognized in clinical practice 2, despite its high prevalence and serious consequences. The disease often serves as the first clinical indication of insulin resistance and metabolic syndrome, preceding complications such as hypertension, coronary heart disease, and type 2 diabetes 7. This underscores the critical importance of screening at-risk populations, particularly those with obesity, diabetes, and metabolic syndrome.